{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:13:39Z","timestamp":1754154819733,"version":"3.41.2"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacl.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:04:28Z","timestamp":1750359868000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-1114","authenticated-orcid":false,"given":"Cameron","family":"Hallihan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-0121","authenticated-orcid":false,"given":"Jianhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floyd","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandita","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Marroquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Mulukutla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-678X","authenticated-orcid":false,"given":"Anum","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.06.011_bib0001","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0002","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype","volume":"63","author":"Sniderman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0003","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0004","series-title":"GeneReviews(\u00ae)","article-title":"Familial hypercholesterolemia","author":"Ison","year":"1993"},{"key":"10.1016\/j.jacl.2025.06.011_bib0005","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024379","article-title":"Cardiovascular risk and treatment outcomes in severe hypercholesterolemia: a nationwide cohort study","volume":"11","author":"Lee","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.06.011_bib0007","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/jcm8071080","article-title":"Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients","volume":"8","author":"Masana","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.06.011_bib0008","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: A review of the recommendations from the National Lipid Association Expert Panel on Familial hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Managed Care Pharm"},{"key":"10.1016\/j.jacl.2025.06.011_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0011","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials","volume":"376","author":"Baigent","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.jacl.2025.06.011_bib0013","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement","volume":"316","author":"Force","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.06.011_bib0014","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.7326\/M14-0126","article-title":"Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology\/American Heart Association Cholesterol Guideline","volume":"160","author":"Stone","year":"2014","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.jacl.2025.06.011_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","article-title":"Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands","volume":"177","author":"Ademi","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jacl.2025.06.011_bib0017","article-title":"Cardiovascular disease risk\u2013Based statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network","volume":"14","author":"Saeed","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0018","article-title":"Statin utilization and cardiovascular outcomes in a real-world primary prevention cohort of older adults","volume":"18","author":"Walker","year":"2024","journal-title":"Am J Prevent Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0019","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.06.011_bib0020","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","article-title":"Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999\u20132014)","volume":"137","author":"Bucholz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0022","article-title":"Sex-based utilization of guideline recommended statin therapy and cardiovascular disease outcomes: data from a multisite healthcare network primary prevention cohort","volume":"18","author":"Koczo","year":"2024","journal-title":"Am J Prevent Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.jacl.2025.06.011_bib0024","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M17-3011","article-title":"Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk","volume":"169","author":"Yadlowsky","year":"2018","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.jacl.2025.06.011_bib0026","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.amjcard.2018.05.008","article-title":"Frequency of statin use in patients with low-density lipoprotein cholesterol \u2265190 mg\/dl from the Veterans Affairs Health System","volume":"122","author":"Rodriguez","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0027","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.5162","article-title":"Rate of statin prescription in younger patients with severe dyslipidemia","volume":"2","author":"Al-Kindi","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0028","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jamacardio.2023.3931","article-title":"Prevalence, awareness, and treatment of elevated LDL cholesterol in US adults, 1999-2020","volume":"8","author":"Sayed","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0029","article-title":"The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US","volume":"12","author":"Saadatagah","year":"2022","journal-title":"Am J Prevent Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","volume":"5","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0031","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0032","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1885-5857(08)60139-5","article-title":"Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy","volume":"61","author":"Alonso","year":"2008","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"10.1016\/j.jacl.2025.06.011_bib0033","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/hrt.2010.213975","article-title":"Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies","volume":"97","author":"Nherera","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2025.06.011_bib0034","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-822992","article-title":"Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands","volume":"4","author":"Wonderling","year":"2004","journal-title":"Semin vasc med"},{"key":"10.1016\/j.jacl.2025.06.011_bib0035","first-page":"385","article-title":"Contemporary trends in the management and outcomes of patients with familial hypercholesterolemia in Canada: a prospective observational study","volume":"33","author":"Brunham","year":"2017","journal-title":"Canad J Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0036","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jacl.2016.09.002","article-title":"Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy","volume":"10","author":"Burke","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0037","first-page":"240","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States","volume":"9","author":"deGoma","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0038","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamacardio.2022.4373","article-title":"Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial","volume":"8","author":"Adusumalli","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.06.011_bib0039","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvn.2019.11.001","article-title":"Improving provider awareness to statin prescribing guidelines: a quality improvement project","volume":"38","author":"Martin","year":"2020","journal-title":"J Vasc Nursing"},{"key":"10.1016\/j.jacl.2025.06.011_bib0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.123.064226","article-title":"Cluster randomized trial of a personalized clinical decision support intervention to improve statin prescribing in patients with atherosclerotic cardiovascular disease","volume":"147","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.06.011_bib0041","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/amiajnl-2012-001145","article-title":"Next-generation phenotyping of electronic health records","volume":"20","author":"Hripcsak","year":"2012","journal-title":"J Am Med Inform Assoc"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:27:04Z","timestamp":1753388824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"alternative-id":["S1933287425003290"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.06.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}